@kujhawk1978

I agree 100% with 0.08 not being of concern on it's own, it is just that this patient has one lymph node positive - I mean, one was found, who knows if there are more : ((( .
Also, I found some studies that discovered that once patient reaches 0.03 post op there BCR is going to happen sooner or later. I am so upset that I did not save the link but this is Google summery :

"The Clinical Meaning of 0.03 ng/mLPredictive Value: Research indicates that a uPSA level of \(0.03 \text{ ng/mL}\) or higher reliably identifies patients who will eventually experience BCR.
Lead-Time Advantage: Traditional BCR is typically defined as a PSA level rising to \(> 0.2 \text{ ng/mL}\). Using the \(0.03 \text{ ng/mL}\) cutoff provides an average "lead time" advantage of roughly 18 months, alerting your care team to rising levels well before traditional thresholds are met.
Independent Marker: Studies (such as the landmark UCLA study) show that achieving an undetectable uPSA (often \(< 0.01 \text{ ng/mL}\)) offers the highest chance of long-term remission, whereas crossing \(0.03 \text{ ng/mL}\) serves as an independent predictor of recurrence regardless of other risk factors."

Wishing you fantastic vacation 😎👍
Enjoy : )))) !!!!